How India Exports Piperacillin to the World

In the United States, piperacillin is approved for various indications, including intra-abdominal infections, nosocomial pneumonia, skin and skin structure infections, female pelvic infections, and community-acquired pneumonia. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for piperacillin, reflecting its established presence in the market. Notably, the combination of piperacillin and tazobactam has been approved for injection, with the FDA's Center for Drug Evaluation and Research (CDER) providing a comprehensive summary review in 2026.

The regulatory pathway for piperacillin involves demonstrating bioequivalence to the reference listed drug, ensuring compliance with the FDA's stringent quality and safety standards. Given the substantial number of Indian exporters (280) supplying piperacillin to the U.S., adherence to FDA regulations is paramount to maintain market access and avoid import alerts.

In the European Union, piperacillin, often combined with tazobactam, is subject to the European Medicines Agency's (EMA) oversight. The EMA has conducted periodic safety update report single assessments (PSUSAs) for piperacillin/tazobactam, with the most recent procedure (PSUSA/00002425/202209) concluding with a maintenance outcome. (ema.europa.eu) This underscores the continuous monitoring of the drug's safety profile.

The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) aligns with EMA standards, requiring marketing authorization holders to comply with EU Good Manufacturing Practice (GMP) guidelines. Indian exporters must ensure their manufacturing facilities meet these stringent GMP requirements to access the EU and UK markets.

Piperacillin is included in the World Health Organization's (WHO) Model List of Essential Medicines, highlighting its critical role in treating severe infections. The drug is also subject to international pharmacopoeia standards, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Compliance with these standards ensures the quality, safety, and efficacy of piperacillin across global markets.

In India, piperacillin is classified under Schedule H of the Drugs and Cosmetics Rules, indicating it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, specific ceiling prices for piperacillin should be verified with the latest NPPA notifications. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with national regulations and international commitments.

Piperacillin's primary patents have expired, leading to a competitive generic market. This patent expiration has facilitated the entry of multiple manufacturers, including Indian exporters, contributing to the drug's widespread availability and affordability globally.

In December 2025, the EMA and the Medicine Shortages Single Point of Contact (SPOC) Working Party closely monitored the supply and availability of specific antibiotics, including piperacillin-tazobactam, across the EU/EEA. As of early December 2025, there were no signs of critical shortages for these antibiotics. (ema.europa.eu)

In January 2024, BD initiated a Class 2 device recall for its BBL Sensi Disc Piperacillin/Tazobactam due to performance issues. This recall underscores the importance of stringent quality control measures in the manufacturing and distribution of piperacillin-related products.

These developments highlight the dynamic nature of the pharmaceutical industry and the necessity for continuous regulatory vigilance to ensure the safety and efficacy of piperacillin in global markets.

Piperacillin, a broad-spectrum β-lactam antibiotic, is primarily manufactured in India, which has established itself as a leading producer of Active Pharmaceutical Ingredients (APIs). However, the production of piperacillin relies heavily on Key Starting Materials (KSMs) and intermediates sourced from China. According to the U.S. Pharmacopeia, 41% of KSMs used in U.S.-approved APIs are solely sourced from China, highlighting a significant dependency on Chinese suppliers.

This dependency poses a substantial risk, as any disruption in the supply chain from China can directly impact the availability of piperacillin. For instance, during the COVID-19 pandemic, stringent lockdowns in China led to supply chain interruptions, affecting the global pharmaceutical industry. Such events underscore the vulnerability associated with concentrated sourcing of critical raw materials.

Our proprietary trade data indicates that the top five Indian exporters account for 73.0% of piperacillin exports, with AUROBINDO PHARMA LTD alone contributing 31.6% ($27.9M USD). This high supplier concentration increases the risk of supply disruptions, as issues affecting these key players—such as regulatory actions, operational challenges, or geopolitical tensions—can significantly impact global supply.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to boost domestic manufacturing of critical APIs and reduce reliance on imports. While this initiative is a positive step, its effectiveness in diversifying the supplier base and reducing single-source dependency remains to be fully realized.

Recent geopolitical tensions have further exacerbated supply chain vulnerabilities. In February 2026, military conflicts led to the closure of the Strait of Hormuz, a critical chokepoint through which approximately 20% of global oil and significant volumes of liquefied natural gas transit. This disruption has caused a surge in energy prices and shipping costs, impacting industries worldwide, including pharmaceutical manufacturing.

Additionally, the Red Sea has experienced increased instability due to attacks on commercial vessels, leading major shipping companies to reroute around the Cape of Good Hope. This detour adds approximately 10 to 14 days to transit times and increases shipping expenses, further straining supply chains.

Compounding these challenges are ongoing U.S.-China trade tensions, which have resulted in tariffs and export restrictions on various goods, including pharmaceutical raw materials. Such measures can disrupt the steady flow of essential components required for piperacillin production, leading to potential shortages and increased costs.

• Diversify Supplier Base: Engage with multiple suppliers across different regions to reduce dependency on a single source for KSMs and intermediates.

• Enhance Domestic Production: Invest in local manufacturing capabilities for critical raw materials to decrease reliance on imports, leveraging government incentives like the PLI scheme.

• Strengthen Supply Chain Resilience: Develop robust contingency plans, including alternative shipping routes and strategic stockpiling of essential materials, to mitigate the impact of geopolitical disruptions.

• Monitor Geopolitical Developments: Establish a dedicated team to track international events that could affect supply chains, enabling proactive risk management.

• Collaborate with Regulatory Bodies: Work closely with organizations such as the FDA and WHO to stay informed about potential regulatory changes and to ensure compliance with international standards.

RISK_LEVEL: HIGH